Literature DB >> 2444291

Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays.

S M Thorpe1.   

Abstract

The presently recognized correlations between various clinical parameters and the concentrations of estrogen and progesterone receptors in breast cancer biopsies are largely based on receptor values obtained using the dextran-coated charcoal (DCC) method. This assay method is highly sensitive to slight changes in assay protocol, and differences in assay methodology may account for the wide variation in proportions of receptor positive patients reported by different centers. A survey of various aspects of the assay method that may lead to reproducible, systematic differences in concentrations of receptor levels is presented; and methods of compensating for or correcting these potential differences are discussed. The following aspects are considered: a) constitution of biopsy tissue, b) method of tissue homogenization, c) absorption of ligands to surfaces, d) inclusion of molybdate in the assay buffer, e) composition of the DCC slurry, and f) handling of samples for liquid scintillation counting. Differences in methods used to homogenize tissue in Europe and the U.S.A. may account for differences observed in the correlation of DCC assay results obtained using the recently-introduced monoclonal ER-EIA technique.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444291     DOI: 10.1007/bf01806378

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  43 in total

1.  Effect of ionic strength on charcoal adsorption assays of receptor-estradiol complexes.

Authors:  E J Peck; J H Clark
Journal:  Endocrinology       Date:  1977-10       Impact factor: 4.736

2.  Abbott monoclonal enzyme immunoassay measurement of estrogen receptors in human breast cancer: a European multicenter study.

Authors:  G Leclercq; H Bojar; J Goussard; R I Nicholson; M F Pichon; A Piffanelli; A Pousette; S Thorpe; M Lonsdorfer
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

3.  Evaluation of various methods for the assay of cytoplasmic oestrogen receptors in extracts of calf uteri and human breast cancers.

Authors:  P W Jungblut; S Hughes; A Hughes; R K Wagner
Journal:  Acta Endocrinol (Copenh)       Date:  1972-05

4.  Multiple steroid receptors in human breast cancer. II. Estrogen and progestin receptors in 672 primary tumors.

Authors:  P M Martin; P H Rolland; J Jacquemier; A M Rolland; M Toga
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

6.  Routine analysis of multiple steroid receptors in human breast cancer.--I--Technological features.

Authors:  P M Martin; P H Rolland; J Jacquemier; A M Rolland; M Toga
Journal:  Biomedicine       Date:  1978-10

7.  Human breast tumor estrogen receptor: effects of molybdate and electrophoretic analyses.

Authors:  L K Miller; F B Tuazon; E M Niu; M R Sherman
Journal:  Endocrinology       Date:  1981-04       Impact factor: 4.736

8.  Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values.

Authors:  C Rose; S M Thorpe; K W Andersen; B V Pedersen; H T Mouridsen; M Blichert-Toft; B B Rasmussen
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

9.  Relationships between steroid receptor and epithelial cell proliferation in benign fibrocystic disease of the breast.

Authors:  J D Jacquemier; P H Rolland; D Vague; R Lieutaud; J M Spitalier; P M Martin
Journal:  Cancer       Date:  1982-06-15       Impact factor: 6.860

10.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.

Authors:  G M Clark; C K Osborne; W L McGuire
Journal:  J Clin Oncol       Date:  1984-10       Impact factor: 44.544

View more
  9 in total

1.  Breast cancer subtypes and survival in chinese women with operable primary breast cancer.

Authors:  Zhao-Sheng Li; Lu Yao; Yi-Qiang Liu; Tao Ouyang; Jin-Feng Li; Tian-Feng Wang; Zhao-Qing Fan; Tie Fan; Ben-Yao Lin; Yun-Tao Xie
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

2.  Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.

Authors:  Liang Shi; Bin Dong; Zhongwu Li; Yunwei Lu; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Zhaoyi Wang; Yuntao Xie
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

3.  Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.

Authors:  C Rosenquist; S M Thorpe; K Danø; J Grøndahl-Hansen
Journal:  Breast Cancer Res Treat       Date:  1993-12       Impact factor: 4.872

4.  Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.

Authors:  E Rønne; G Høyer-Hansen; N Brünner; H Pedersen; F Rank; C K Osborne; G M Clark; K Danø; J Grøndahl-Hansen
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

5.  Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals.

Authors:  H R Andersen; A M Andersson; S F Arnold; H Autrup; M Barfoed; N A Beresford; P Bjerregaard; L B Christiansen; B Gissel; R Hummel; E B Jørgensen; B Korsgaard; R Le Guevel; H Leffers; J McLachlan; A Møller; J B Nielsen; N Olea; A Oles-Karasko; F Pakdel; K L Pedersen; P Perez; N E Skakkeboek; C Sonnenschein; A M Soto
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

6.  Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.

Authors:  H Helin; J Isola; M Helle; T Koivula
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

7.  Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

Authors:  A Knoop; P A Andreasen; J A Andersen; S Hansen; A V Laenkholm; A C Simonsen; J Andersen; J Overgaard; C Rose
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

8.  Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.

Authors:  C M Ferrier; H H de Witte; H Straatman; D H van Tienoven; W L van Geloof; F J Rietveld; C G Sweep; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

9.  Binding sites of droloxifene in the cytosol of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.

Authors:  I Kawamura; E Lacey; Y Tanaka; F Nishigaki; T Manda; K Shimomura
Journal:  Jpn J Cancer Res       Date:  1994-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.